Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMarin’s chief medical officer to retire
Dr Kakkis has decided to leave his position with the company to allow him to be able to devote more of his time to personal endeavors related to
Dr Kakkis has decided to leave his position with the company to allow him to be able to devote more of his time to personal endeavors related to
The depositary for the tender offer has advised Lilly and ImClone that, as of the expiration of the tender offer, approximately 85.40 million shares (including 5.17 million shares
The Committee for Medicinal Products for Human Use’s (CHMP) positive opinion is now referred for final action to the European Commission. Subject to approval by the European Commission,
The recommendation by the Committee for Medicinal Products for Human Use (CHMP) is based on results from the first randomized placebo-controlled trial of a biologic treatment in children
The company sold one million shares of common stock at $1.10 per share. The investors also received warrants to purchase an additional 150,000 shares of common stock at
The new company will be named Life Technologies Corporation and will be traded on the NASDAQ global select market under the ticker symbol ‘LIFE’ beginning November 24, 2008.
Dr Svensson is currently the director of the Center for Aortic Surgery and director of the Marfan syndrome and Connective Tissue Disorder Clinic in the department of thoracic
As under the previous agreement, Toshiba will offer Vital Images’s solution through its subsidiaries and distributors in more than 50 nations in North and South America, Europe, the
This acquisition brings in-house critical core competencies – the development of 3D volume rendering and advanced visualization capabilities for all Toshiba modalities. Toshiba is patterning this acquisition after
As previously announced, the financing was led by TVM Capital and included participation from new investors Mizuho Capital, Morningside Group and Japan Asia Investment Co. Existing Argos investors